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Background: Vilazodone is the latest approved antidepressant available in the United States. 
Its dual mechanism of action combines the inhibition of serotonin transporters while simultane-
ously partially agonizing serotonin-1a (5-HT1A) receptors. This combined activity results in 
serotonin facilitation across the brain’s serotonergic pathways, which has been termed by the 
authors as that of a serotonin partial agonist and reuptake inhibitor, or SPARI.
Objective: The authors to review laboratory, animal model data, and human trial data to 
  synthesize a working theory regarding the mechanism of antidepressant action of this agent 
and regarding its potential for additional indications.
Methods: A MEDLINE and Internet search was conducted and the resultant evidence 
reviewed.
Results: Vilazodone has randomized, controlled empirical data which has garnered it an 
approval for treating major depressive disorder. It combines two well-known pharmacodynamic 
mechanisms of serotonergic action into a novel agent. Although no head-to-head studies against 
other antidepressants are published, the efficacy data for vilazodone appears comparable to 
other known antidepressants, with associated gastrointestinal side effects similar to serotonin 
selective reuptake inhibitor and serotonin norepinephrine reuptake inhibitor antidepressants, 
but potentially with a lower incidence of sexual side effects and weight gain.
Discussion: As a new option for the treatment of major depressive disorder, vilazodone, due 
to its unique SPARI mechanism of action, may hold promise for patients who cannot tolerate 
or have not responded to previous antidepressant monotherapies. Additionally, its use may 
extend to the treatment of other mental health conditions similar to those treated by serotonin 
selective reuptake inhibitors.
Keywords: major depressive disorder, vilazodone, antidepressants
Introduction
Vilazodone is now a US Food and Drug Administration (FDA)-approved antidepres-
sant treatment (ADT). This paper will review preclinical pharmacokinetic information, 
pharmacodynamic information, current publicly available clinical data for this product, 
as well as reviewing animal models and mechanism of action data that would suggest 
potential use in other realms of psychiatric illness.
Clinicians have been using the same catecholamine treatments for major depressive 
disorder (MDD) since the 1950s, mostly by blocking reuptake transporters (dopamine, 
norepinephrine, and serotonin). Originally utilizing the tricyclic antidepressants, 
and in recent years, more so with serotonin selective reuptake inhibitors (SSRIs) 
and serotonin norepinephrine reuptake inhibitor (SNRIs). The National Institute of 
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Mental Health’s STAR*D trial suggests that remission from 
a prototypical agent of the SSRI class occurs one-third of 
the time with initial monotherapy in MDD patients, and each 
subsequent ADT yields less favorable outcomes as treat-
ment resistant depression increases. After four successive 
ADTs, about two thirds of patients finally remit, but many 
of these do not sustain their remission for more than a few 
months.1 Therefore, one third of MDD patients continue to 
have significant symptoms after treatment with a sequence 
of agents for about a year, and many of those who remit do 
not sustain their improvement. Given these modest results, 
researchers continue to investigate ways to treat MDD with 
novel pharmacologic mechanisms.
In the absence of a remarkable breakthrough drug in 
the area of nonmonoamine agents, ie, hormonal, peptide, 
genetic, neuromodulation,2 clinicians have resorted to higher 
levels of polypharmacy to gain full remission when mono-
therapies fail. Combination drug treatment might be being 
deployed earlier and earlier in treatment as an option.1,3,4 To 
boost antidepressant efficacy in patients who fail to respond 
adequately to a SSRI, second generation atypical antipsychot-
ics are FDA-approved (aripiprazole, quetiapine, quetiapine 
XR, olanzapine-fluoxetine combination), but with potential 
additional side effect burden (metabolic and movement 
  disorders) and cost.5,6 A unique mechanistic approach occurs 
with vilazodone, an agent that combines two mechanisms in 
a single drug, namely that of a SSRI with 5-HT1A   receptor 
partial agonist actions serotonin partial agonist reuptake 
inhibitor (SPARI).7 Specifically, this agent increases the 
availability and activity of the neurotransmitter serotonin and 
its neuropathways. Vilazodone blocks the serotonin reuptake 
pump (serotonin transporter), desensitizes serotonin receptors 
(especially serotonin 1A autoreceptors), and therefore pre-
sumably increases serotonergic neurotransmission. Its partial 
agonist actions at presynaptic somatodendritic 5-HT1A 
autoreceptors may theoretically enhance serotonergic activity 
and contribute to antidepressant actions as well.1,8,9 This par-
tial agonist action also occurs at the level of the postsynaptic 
5-HT1A receptor which may theoretically diminish sexual 
dysfunction.8,9 This effect has been noted in studies utilizing 
the 5-HT1A receptor partial agonist, buspirone.10 In support 
of this theoretical information, similar animal models suggest 
potential for rapid onset antidepressant efficacy, given more 
robust serotonergic actions suggesting greater antidepressant 
efficacy compared to SSRIs.11–13 However, these preclinical 
suggestions have yet to be confirmed specifically for vila-
zodone in human clinical trials. Currently there is a lack of 
head-to-head comparative trials with other antidepressants. 
This makes potential efficacy and tolerability comparisons 
to known ADT agents difficult. What is known about the 
pharmacokinetics, pharmacodynamics, and clinical trial 
results of vilazodone and animal models could suggest further 
applications for this novel mechanism. This information will 
be reviewed shortly.
Vilazodone pharmacokinetics
According to the official FDA-sanctioned package 
insert,14 this drug is initially dosed at 10 mg per day in 
the morning for 1 week then dose escalated to 20 mg per 
day for week 2 with the final titration to the 40 mg per 
day as a usual daily dose. It comes in 10 mg, 20 mg, and 
40 mg tablet strengths. This drug must be taken with food 
or 50% of its bioavailability is lost. There are no dosing 
changes required in renal or hepatic patients and a gradual 
withdrawal is suggested to avoid serotonin discontinuation 
syndrome. Its moderate half-life makes withdrawal 
possible, but likely with a low severity of symptoms. 
It is clinically contraindicated for use with monoamine 
oxidase inhibitors. Vilazodone is metabolized extensively 
by the hepatic CYP450 3A4 enzyme system. Its dose 
should be reduced to 20 mg/day with concomitant use of 
potent 3A4 inhibitors (erythromycin, amiodarone, protease 
inhibitors, ketoconazole). Vilazodone’s therapeutic activity 
is due primarily to the parent drug and there are no known 
active metabolites. The pharmacokinetics of vilazodone 
(5 mg–80 mg) are dose-proportional. Steady-state is often 
achieved in days. Vilazodone has a terminal half-life of 
approximately 25 hours. It is 96%–99% protein-bound so it 
may disrupt digoxin- or coumadin-binding temporarily as it 
displaces these drugs into a nonprotein-bound, free plasma 
state which increases their availability and activity.
Vilazodone pharmacodynamics
Vilazodone is a combined serotonin reuptake inhibitor (SRI) 
and 5-HT1A receptor partial agonist.15 The authors use the 
term SPARI to define this class of ADT.7 This mechanistic 
way of treating MDD is similar to the common depres-
sion treatment strategy of augmenting SSRI monotherapy 
(fluoxetine, sertraline, paroxetine, etc) with the commer-
cially available 5-HT1A receptor partial agonist anxiolytic, 
buspirone.16 The latter is approved for treating generalized 
anxiety disorder (GAD).7 In fact, the STAR*D trial has 
studied nonremitters to treatment with citalopram, comparing 
augmentation with either buspirone or with bupropion SR, 
finding no significant differences in remission rates between 
these two combination treatments.17
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SRI mechanisms yield an increase in synaptic 5-HT 
through serotonin transporter reuptake inhibition. This pro-
duces a desensitization and/or downregulation of presynaptic 
5-HT1A autoreceptors. As these autoreceptors are now 
over stimulated, the 5-HT neuron interprets this initially as 
toxic activity. As these autoreceptors become less effective 
due to over stimulation and desensitization, they offer less 
autoreceptor inhibition to the 5-HT neuron and excess 5-HT 
is next released at the neuron terminals as a result. By directly 
agonizing the 5-HT1A receptors in the central nervous 
  system, vilazodone likely allows a faster or greater volume 
of 5-HT1A receptor desensitization/downregulation up front. 
This may lend more additive or synergistic 5-HT effects than 
SSRI alone. Thus, the rationale behind this pharmacodynamic 
combination is to yield a faster and larger scale desensitiza-
tion of the somatodendritic 5-HT1A autoreceptor system in 
MDD patients. This mechanism essentially lowers the 5-HT 
neurons’ ability to regulate 5-HT output, thus increasing 
5-HT neuronal firing and activity. This more aggressive, or 
synergistic, 5-HT facilitation approach may then directly 
stimulate postsynaptic 5-HT1A heteroreceptors downstream 
which may actually promote even more neuronal firing and 
activity of 5-HT or other monoamine neurons.13
The recent review by Athanasiou, Reed, and Rickels 
suggests that in vitro studies show that vilazodone is more 
highly selective for the 5-HT1A receptor than for other neu-
ronal receptors and its affinity (50% inhibitory concentration 
[IC50] nM) is 0.5 compared to a lower affinity buspirone 
anxiolytic.18 The 5-HT1A receptors are presynaptic receptors 
located in the raphe nuclei where they act as autoreceptors to 
inhibit the firing rate of 5-HT neurons. The 5-HT1A receptors 
are also located on postsynaptic cells in limbic and cortical 
regions where they can also lower firing.
Although this theoretical thinking underlies the develop-
ment of vilazodone as a potentially novel antidepressant drug, 
there is as yet no clinical human evidence of rapid onset or 
more robust antidepressant action compared to SSRI/SNRI 
antidepressants. The presence of gastrointestinal side effects 
causes the need for slower titration of vilazodone starting at 
lower than the maintenance dosing for 2 weeks, thus poten-
tially delaying any potential rapid onset effect in patients for 
better tolerability.
As there are limited animal models and no direct 
  vilazodone head-to-head comparative trials available, a 
single, monotherapy agent like vilazodone that combines 
these same pharmacologic actions as the combination of a 
SSRI with buspirone should be able to provide the poten-
tial efficacy benefits of this combination, particularly if 
  administered early in treatment.19,20 Instead of starting with 
a SSRI monotherapy with dose escalation for 12 weeks, 
waiting for it to potentially fail (two of three times per 
STAR*D) followed by the subsequent augmentation addition 
of buspirone for another several weeks, vilazodone allows 
immediate, simultaneous combination of these two pharma-
codynamic properties at the outset of treatment. Athanasiou 
et al reviewed the pharmacogenetics associated with vila-
zodone which in theory might allow clinicians to genetically 
test which patients might respond more fully to vilazodone 
and perhaps detect who will experience adverse side effects. 
Regarding gastrointestinal side effects, genetic biomarkers 
(M2-) may suggest those with a 10-fold increase in risk of 
severe gastrointestinal   distress. Finally, patients with M1+ 
genetic markers are more likely to have full antidepressants 
effect towards remission with a relative risk of 2.1.18
Overall, this product is not as complex or risk-laden as 
a second generation atypical antipsychotics augmentation 
approach in treating MDD, it would in theory allow less side 
effect burden, especially given its absence of metabolic and 
movement disorders. A full discussion of the clinical effec-
tiveness and adverse effects of vilazodone are forthcoming. 
Unfortunately, these considerations and comparisons to 
STAR*D outcomes remain merely theoretical since there are 
no studies reporting the comparison of vilazodone to other 
active treatments or combinations of treatments.
Serotonin and brain circuitry:  
a primer
This circuitry is reviewed to indicate where vilazodone may 
exert its effects and also to alert the reader to better under-
stand the forthcoming discussion regarding vilazodone’s 
preclinical data.
Serotonergic pathway projections include the spinal 
cord, brainstem cortical, and subcortical structures. The 
5-HT system originates from neurons of the brainstem raphe 
nuclei and project widely throughout the brain to regulate 
many functions, including sleep, mood, and stress r  eactivity. 
These are implicated in the pathogenicity of MDD and 
anxiety disorders.21
The ascending serotonergic pathways project from 
the raphe to the amygdala, the paralimbic entorhinal and 
dentate gyrus, the rectus gyrus of the frontal lobe, and the 
inferior and superior gyri of the temporal lobe. Multiple 
5-HT receptors have been implicated including 5-HT1A, and 
5-HT1B/5-HT1C which are found in different areas of the 
brain that interact with the hypothalamic–pituitary–adrenal 
(HPA) axis. In particular 5-HT1A receptors in man, rat, 
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and guinea pig are found in high concentration in the dorsal 
raphe nuclei (presynaptic), the hippocampus (postsynaptic), 
the lateral septum, the frontal cortex, and the dorsal horn of 
the spinal cord.21
Evidence has shown a lower density of 5-HT1A r  eceptor 
sites in the amygdala and hippocampus in depressed 
patients which may be related to the increased HPA activity 
consistent with increased glucocorticoid secretion found 
in these patients. This increased activity of the HPA axis 
is related to increased corticotrophin-releasing hormone, 
  potentiating effects of increased arginine vasopressin secre-
tion on   corticotrophin-releasing hormone-induced ATCH 
secretion which may be due to the diminished central 5-HT 
  neurotransmission that allows for the negative feedback of 
this system.20 Therefore, not only does serotonergic dysfunc-
tion itself play a role in MDD and anxiety disorders, but the 
interplay with the HPA axis and 5-HT1A receptors are of 
special interest.
Vilazodone in animal studies
The role of 5-HT in regards to its anxiolytic effect has 
been illustrated in rodent distress vocalization studies in 
the expression of ultrasonic calls of infant rat pups   during 
brief maternal separations.21 In this model there was a 
reduction in the rate of calling after acute administration of 
SSRIs to 9–11-day-old pups. Similarly, acute administra-
tion of the 5-HT1A agonists buspirone, 8-OH-DPAT and 
ipsapirone reduced the rate of calling at doses that did not 
affect motor activity or core body temperature.22 In similar 
ultrasonic vocalizations studies using vilazodone, stress-
induced vocalizations were inhibited as well (55 mg/kg po) 
at 120 minutes and 210 minutes post-dose. In contrast, 
the SSRI fluoxetine (100 mg/kg po) was without effect 
unless combined with 8-OH-DPAT. This suggests that the 
5-HT1A receptor agonist activity in vilazodone contributed 
immensely to its efficacy.23
In two other rat study models for anxiety, vilazodone 
demonstrated dose-related efficacy (10–40 mg/kg ip) in the 
shock probe test24 which measures the defensive burying 
behavior by a rat in response to anxiety provoking stressors 
(a shock by stationary electrified probe), but no significant 
effect was found in the elevated plus maze where the animal 
is placed in the center of an elevated four-arm maze (two 
arms which are open and well lit and two arms that are 
enclosed and dimly lit). The time the rat spends on each arm 
is recorded. Rats usually prefer the closed arms but when 
effective anxiolytics are administered they increasingly enter 
the open arms with more propensity.23,25
Vilazodone was also examined in a predator-induced 
stress paradigm, when exposure to a domestic cat would 
result in additional increased anxiety-like behaviors in the 
elevated plus maze and an increased response to an acoustic 
startle. Diminished stress-induced potentiated startle were 
observed when vilazodone (20–40 mg/kg ip) was adminis-
tered acutely or prophylactically (1 week prior to behavioral 
testing), but had no effect on stress potentiated anxiety 
response in the elevated plus maze.26
In studying vilazodone antidepressant-like activity, two 
instances using the forced swim test, which are often used to 
screen for effective antidepressants, revealed some support 
for this effect. Rats who were injected with three doses of 
vilazodone (1 mg, 3 mg, and 10 mg/kg) prior to the swim 
test showed reduced immobility and increased swimming 
behavior although only significant changes were observed 
at the 1 mg/kg dose. Swimming was defined as horizontal 
movement through a swim chamber which included crossing 
into another quadrant in a 5-minute swim test after being 
placed in a cylinder full of water for 15 minutes. In the 
mouse forced swim test similar results were produced at the 
1 mg/kg dose, however, no significant changes were observed 
at 0.3 mg/kg and 3 mg/kg doses. These are consistent with 
patterns observed with conventional SSRIs such as fluoxetine 
in the past.27,28
In vitro tests demonstrated that vilazodone has serotonin 
neurotransmission enhancing potential in part due to robust 
blockade of the serotonin transporter and in part to direct 
partial agonist actions on 5-HT1A receptors.27 In fact, one 
such study revealed that vilazodone increased cortical 5-HT 
levels more than a SSRI (fluoxetine) alone, making intuitive 
sense in two serotonergic mechanisms, which should have 
additive cortical effects. In the rat cerebral cortex vilazodone 
inhibited serotonin reuptake 30 times more than fluoxetine.29 
  Alternatively, one study revealed that vilazodone behaved 
essentially as a SSRI in the guinea pig dorsal raphe, using 
voltammetric measures of 5-HT, but displayed no evidence of 
direct agonism at 5-HT1A receptors,27 fostering controversy 
over 5-HT additive or synergistic effects in animal models.
Vilazodone in human studies
In a double-blind placebo-controlled crossover in vivo study 
with ten healthy males, the effect of vilazodone at 20 mg 
and 40 mg was assessed on sleep electroencephalography, 
suggesting that at the 40 mg dose it preferentially occupied 
presynaptic versus postsynaptic 5-HT1A receptors.27
Although in vivo data has shown some inconsisten-
cies in its action as an agonist at pre-and/or postsynaptic 
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5-HT1A receptors, vilazodone does enhance forebrain 
serotonergic output and is efficacious in preclinical models 
of anxiety and depression regardless.13
Taking into account studies showing partial agonism at 
the 5-HT1A receptors increasing serotonin levels in brain 
areas relevant to depression and the synergy achieved in 
combination with a SSRI, vilazodone’s 5-HT effect may be 
more pronounced due to additional data suggesting that it is 
60 times more selective for the 5-HT1A receptor   compared 
with buspirone with an IC50 of 0.5 nM versus 30 nM for 
buspirone. Vilazodone is also approximately 30 times 
more selective at blocking serotonin reuptake compared to 
fluoxetine with an IC50 of 0.2 nM versus 6 nM.28
In vivo vilazodone was more potent than fluoxetine 
at inhibiting serotonin reuptake in mouse hypothalamic 
synaptosomes.29
Initial human studies showed sleep architecture changes 
consistent with other approved antidepressants.30 Dawson’s13 
review outlines phase II studies in a succinct manner where 
vilazodone was administered to a total of 369 healthy 
subjects and 1163 depressed subjects, but failed to demon-
strate significant efficacy against placebo initially. Of note, 
active comparator studies here also failed to demonstrate 
efficacy versus placebo. However, subsequent clinical trials 
have demonstrated statistical significance against placebo in 
phase III trials for MDD.31 This suggests some controversy 
where some studies were positive and some negative. The 
more current, larger scale studies with improved statistical 
power and design have suggested enough separation from 
placebo to allow FDA approval. Vilazodone was well toler-
ated, with the most commonly observed adverse events being 
diarrhea, nausea, somnolence, and dizziness. An FDA new 
drug application occurred in 2009 and secondary, regulatory 
trials again suggested antidepressant efficacy and tolerability. 
Vilazodone was approved for MDD in January 2011.
The official company data and FDA package insert14 
reveals this positive regulatory confirmatory trial information. 
Vilazodone was effective in two pivotal short-term studies, 
double-blind phase III studies both 8 weeks in length.
One a randomized, controlled trial where 410 subjects 
aged 18–65 years found significant improvements in 
multiple depression rating scales when compared to placebo. 
Effectiveness was assessed with the Montgomery–Asberg 
Depression Rating Scale and clinical global impressions 
scales as well as with the 17-item Hamilton Rating Scale. 
Diarrhea, nausea, and somnolence were the greatest 
side effects noted. There were clinically no significant 
differences for either gender in regards to sexual dysfunction 
outcome measures.32   Vilazodone efficacy in MDD was further 
established in 8-week, multicenter, randomized, double-
blind, placebo-controlled studies in adult (18–70 years of 
age) outpatients who met the Diagnostic and Statistical 
Manual of Mental Disorders33 criteria for MDD. Vilazodone 
was superior to placebo in the improvement of depressive 
symptoms, and evaluation of population subgroups based 
on age, gender, and race did not reveal any clear evidence 
of differential responsiveness. Its most common side effects 
over placebo included diarrhea, nausea, and dry mouth 
and does carry the increased lethality warning in young 
adult patients. It is not approved for pediatric depression. 
No blood laboratory or EKG changes were noted and none 
are required while administering this ADT. In these acute 
8-week studies no abnormal weight gain or metabolic adverse 
effects were noted.14 Finally, sexual dysfunction adverse 
effects were minimal (1%–2% over placebo rates only).7 Of 
course, minimal side effects in these areas still suggest that 
they may occur and some studies show better tolerability 
than others.
Additional phase II studies were all 8 weeks and used 
the Hamilton Rating Scale as primary endpoints while using 
the Montgomery–Asberg Depression Rating Scale and clini-
cal global impressions as secondary endpoints. Reviews of 
previous studies showed significant secondary endpoint 
improvement in clinical global impressions severity score 
as did a second placebo controlled study using fixed dose 
scheme while again no significant differences were found 
between placebo and treatment for primary outcomes.31
In two more phase II studies, vilazodone and fluoxetine 
at typical starting doses were compared against placebo, no 
significant difference was found versus placebo in primary 
outcomes but were statistically significant in secondary 
outcomes.31
In regard to long term studies, a 52 week open label study 
including 616 patients aged 18–70 years found improvement 
in Montgomery–Asberg Depression Rating Scale scores over 
this time period. They concluded vilazodone 40 mg/day for 
1 year was safe and well tolerated by adults with MDD.34
Additionally, a review of data from 24 human trials which 
included 2898 human subjects exposed to one or more doses 
of vilazodone concluded that it was as effective as SSRIs, 
however, stated it to be unknown if it had any advantages 
over others in its class.35
Other clinical applications
Given that other agents with SSRI activity and 5-HT1A 
receptor activity carry approvals for depression, GAD, 
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obsessive compulsive disorder (OCD), social anxiety 
  disorder (SAD), panic disorder, posttraumatic stress disorder, 
eating disorders, and premenstrual disorders,7,36 it would fol-
low that vilazodone conceptually has the pharmacodynamic 
mechanisms necessary to alleviate symptoms attributed to 
these disorders as well.
GAD
Currently buspirone is FDA-approved for treatment of GAD. 
Studies have shown similar effects compared to various 
benzodiazepines without dependence and discontinuation 
issues22 which are a benefit especially in specific populations 
with substance abuse history or the elderly. By extension 
of this similar mechanism of action, vilazodone could be 
a feasible option in treatment resistant GAD and given the 
50% comorbidity with MDD, would be beneficial in these 
cases as well, due to its antidepressant effect.
Alcohol abuse
Studies using buspirone have been conducted and shown 
to reduce anxiety and cravings in patients with alcohol 
d  ependence.22 In a placebo-controlled double-blind trial 
involving 51 subjects, buspirone was superior to placebo in 
reducing the number of days craving alcohol. This is a poten-
tially advantageous use for vilazodone due to the common 
comorbid diagnosis of depression with alcohol dependence 
in one third of these patients.37
OCD
A small open-label study38 found some benefit from nine 
out of eleven patients with OCD when buspirone was added 
to fluoxetine which replicates the SPARI mechanism of 
vilazodone. However, a subsequent placebo-controlled 
double-blind study did not show an advantage over placebo 
in similar augmentation of bupsirone.39 Therefore, although 
there may be a role for 5-HT1A agonism in OCD treatment 
more studies are required to fully explore this combination 
treatment as a viable option. It is likely that vilazodone doses 
would need to be utilized greater than 40 mg/day, similar to 
the excessive SSRI doses needed to treat OCD.
SAD
In a study40 with 21 social phobia patients, 47% showed 
modest improvement when using buspirone in an open 
12-week trial. Comparable results were shown in another 
open buspirone trial26 which could suggest a role for vila-
zodone for the treatment of SAD with its built-in 5-HT1A 
partial agonist mechanism.
Also, since 40 mg only occupies an estimated 50% of 
serotonin transporters and 5-HT1A receptors,41 it seems 
reasonable to test doses in the 50–80 mg/day range by slow 
upward titration, especially for treatment resistant cases of 
depression and other related disorders.
Conclusion
Vilazodone has been approved for treatment of MDD. 
Usual treatment guidelines42 should be followed in regards 
to making an accurate   diagnosis, ruling out bipolarity, sub-
stance misuse, and personality   disorders prior to its use. If 
an ADT is warranted, monotherapy with an approved agent 
with a good risk/  benefit should be chosen. Vilazodone 
should be acceptable as a first-line agent as its combined 
SPARI mechanism offers a unique initial antidepressant 
approach when compared to SSRI, SNRI, etc. The dose of 
vilazodone must be more fully explored as well, because a 
clear “no effect” dose has not been established and a 20 mg 
dose trial will be required as a condition of approval, as 
will studies in children and longer term relapse prevention 
studies in depression. Vilazodone, however, will likely be 
used in those who do not respond to a SSRI/SNRI or do 
not tolerate a SSRI/SNRI given their prevalence and ease 
of use as well as potential for faster titration and lower 
gastrointestinal side effect profiles. Vilazodone may be 
especially useful if the patient develops sexual dysfunction, 
weight gain, or increased blood pressure on these agents, and 
should strongly be considered secondarily, if patients can-
not tolerate or risk intervention with an atypical second 
generation antipsychotic augmentation trial due to weight 
gain, sedation, extrapyramidal symptoms, or dyslipidemia. 
Additionally, in examination of its mechanism of action being 
similar to SSRIs plus   buspirone, as well as results from its 
animal model studies, its clinical application can be theoreti-
cally broadened off label for the treatment of other psychiatric 
disorders, especially if initial approved drug trials fail.
In regards to future investigations, given this products 
dual action manipulation of serotonergic processes it should 
undergo extensive clinical trial investigation for the treatment 
of SAD, panic disorder, OCD, posttraumatic stress disorder, 
bulimia nervosa, and premenstrual dysphoric disorder com-
parable to those indications held by current SSRI and SNRI 
antidepressant products.
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